Barriers and facilitators to the implementation of pharmacogenomic testing for antidepressants use in primary care: a systematic review using the consolidated framework for implementation research.
Muireann Counihan, Deirdre Cushen, Sookyung Kwak et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review examined barriers and facilitators to implementing pharmacogenomic (PGx) testing for antidepressant use in primary care, utilizing the Consolidated Framework for Implementation Research (CFIR). Thirteen studies involving various stakeholders were analyzed. Key barriers identified included limited perceived evidence and cost uncertainty, while facilitators included pharmacist-led support and interprofessional collaboration.
Key findings
- Barriers to PGx testing included limited perceived evidence and workflow disruption.
- Facilitators included pharmacist-led support and adaptable delivery models.
- Implementation is constrained by issues of clinical utility and cost.
Why it matters
Understanding the barriers and facilitators to PGx testing can help clinicians and healthcare systems improve antidepressant prescribing practices, potentially enhancing patient outcomes through more personalized treatment approaches.